Berkshire Hathaway Has a Cash Problem Most Companies Would Love to Have

Berkshire Hathaway ended Q1 with $390.7 billion in cash, cash equivalents, and short-term U.S. Treasury investments, up 14% year over year and larger than the market caps of many major companies. Warren Buffett said Berkshire is willing to pursue acquisitions, but only at sensible prices, after opting for a $9.7 billion OxyChem purchase instead of a larger deal. The article is mostly a valuation and capital-allocation discussion, with limited immediate market impact.

Analysis

Berkshire’s cash hoard is less a sign of caution than a signal that the public large-cap opportunity set is thin at acceptable prices. That matters because Berkshire is one of the few natural buyers capable of absorbing a multi-10B acquisition without financing stress; its inactivity is effectively a negative liquidity indicator for the upper end of the market. When the buyer of last resort won’t step up, it tends to compress M&A multiples broadly, especially for complex industrial and cash-generative assets where diligence risk is highest.

The second-order winner is OXY, not because the company is strategically transformed, but because Berkshire’s prior behavior creates a de facto valuation floor and optionality on further asset monetization or balance-sheet support. By contrast, the market’s “Berkshire cash is dead money” narrative may be too simplistic: large cash balances become a call option on dislocation, and in a late-cycle tape that option can be worth more than incremental equity risk. The opportunity cost is that Berkshire’s capital deployment pause may keep underwriting and deal activity subdued in adjacent sectors for several quarters.

The contrarian read is that this is a timing issue, not a thesis break. If volatility spikes or credit spreads widen, Berkshire can move quickly, while smaller acquirers cannot; that asymmetry means the current cash pile is latent firepower, not idle capital. The risk is that investors overestimate near-term deployment and underappreciate how long Berkshire can wait—months or even years—while earning acceptable Treasury-like carry and preserving dry powder for a true reset in market pricing.

Key Decisions for Investors

• Maintain a tactical long BRK.B versus a basket of expensive mega-cap compounders for 3-6 months; downside is limited by cash optionality, while upside improves if market multiples compress and Berkshire redeploys capital.
• Keep OXY on a relative-value watchlist as a low-beta beneficiary of Berkshire’s strategic footprint; use pullbacks to build a position with a 6-12 month horizon, targeting asymmetric upside if capital allocation support becomes more visible.
• Fade high-multiple, acquisitive industrials with heavy M&A dependence via a short basket against BRK.B; if Berkshire is unwilling to transact at current prices, the discount-rate regime is likely too tight for aggressive buyers.
• Sell near-dated volatility in BRK.B only if upside catalysts remain absent; the cash overhang lowers left-tail risk, but the real convexity is to a surprise acquisition during a market dislocation.